Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Core Insights - Longeveron Inc. announced the publication of results from the CLEAR MIND Phase 2a clinical trial for laromestrocel (Lomecel-B™) as a potential treatment for mild Alzheimer's disease, reinforcing its safety and efficacy [1][2] Clinical Trial Details - The Phase 2a trial involved 48 patients aged 60-85 with mild Alzheimer's disease, where 36 received laromestrocel and 12 received a placebo [2][3] - The trial achieved its primary safety and secondary efficacy endpoints, with results published in Nature Medicine [2][3] Key Findings - Laromestrocel (Lomecel-B™) improved cognitive function, quality of life, and brain volume in patients with mild Alzheimer's disease [3] - The treatment demonstrated safety and tolerability, with no significant adverse effects reported [4] - Statistically significant improvements were observed in cognitive assessments and brain volume preservation compared to placebo [4] Mechanism of Action - Laromestrocel is a mesenchymal stem cell therapy that may address inflammatory responses in the brain, offering a new strategy for treating Alzheimer's disease [2][6] - The therapy has multiple potential mechanisms, including pro-vascular and immunomodulatory effects [6][7] Regulatory Designations - Laromestrocel (Lomecel-B™) has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for the treatment of mild Alzheimer's disease [5][7] Future Development - The company plans to meet with the FDA to discuss the data and future development paths for laromestrocel in Alzheimer's disease [5]